Pelthos Therapeutics Inc. (PTHS) Stock Ticker
Market factors today
Unlock the full PTHS picture
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
PTHS stock facts
| Ticker symbol | PTHS |
| Exchange | New York Stock Exchange Arca |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $77.1M |
| CEO | Scott Plesha |
| Employees | 92 |
| Headquarters | Durham, NC, US |
| IPO date | 2024-02-16 |
| Website | pelthos.com |
What you can see for PTHS on Tickr
Live PTHS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PTHS report.
Rankings
FAQ
What is the ticker symbol for Pelthos Therapeutics Inc.?
The ticker symbol for Pelthos Therapeutics Inc. is PTHS, listed on the New York Stock Exchange Arca.
What is PTHS?
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an…